U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799195) titled 'Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation' on Jan. 15.
Brief Summary: This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Hematological Malignancies
Graft-versus-Host Disease (GVHD)
Intervention:
DRUG: Attenuated-dose Cyclophosphamide
Cyclophosphamide administered at an attenuated dos...